Search

Displaying results 3961 - 3970 of 4584 in total
  1. Drug

    Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15562
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Gamolenic acid

    go.drugbank.com/drugs/DB13854
    ApprovedWithdrawn

    Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds that is most commonly found in human milk and other botanical sources . It is an ome...

  3. Drug

    Alphameprodine

    go.drugbank.com/drugs/DB01499
    ExperimentalIllicit

    Alphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.

  4. Drug

    Betameprodine

    go.drugbank.com/drugs/DB01552
    ExperimentalIllicit

    Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.

  5. Drug

    Imidacloprid

    go.drugbank.com/drugs/DB11421
    ExperimentalVet approved

    Imidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise

  6. Drug

    Orgotein

    go.drugbank.com/drugs/DB11444
    ExperimentalVet approved

    Hydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum.

  7. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with

  8. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which